BACKGROUND: Many potentially inappropriate drugs prescribed to older people have anticholinergic properties as adverse effects and are therefore potentially harmful. These effects typically include constipation, dry mouth, blurred vision, dizziness and slowing of urination. It has been shown that drugs with anticholinergic properties (DAPs) are associated with cognitive decline and dementia, may contribute to events such as falls, delirium and impulsive behaviour, are associated with self-reported adverse effects and physical impairment, and may even be associated with mortality. However, studies of the prognostic implications of DAPs remain scarce. OBJECTIVE: To evaluate the impact of DAPs on hospitalization and mortality in older patients with stable cardiovascular disease (CVD). METHODS: This was a prospective study with a mean follow-up of 3.3 years involving two study groups: users (n = 295) and non-users (n = 105) of DAPs. The participants were 400 community-dwelling older people (aged 75-90 years) with stable CVD participating in a secondary prevention study of CVD (DEBATE) in Helsinki, Finland. The use of DAPs was estimated using definitions from the previous scientific literature. The Charlson Comorbidity Index (CCI) was used to estimate the burden of co-morbidity and the Mini-Mental State Examination test was used to assess cognitive function. The risks in the two study groups for hospital visits, number of days spent in hospital care and mortality were measured from 2000 to the end of 2003. RESULTS: The unadjusted follow-up mortality was 20.7% and 9.5% among the users and non-users of DAPs, respectively (p = 0.010). However, the use of DAPs was not a significant predictor of mortality in multivariate analysis after adjustment for age, sex and CCI score (hazard ratio 1.57; 95% CI 0.78, 3.15). The mean ± SD number of hospital days per person-year was higher in the DAP user group (14.9 ± 32.5) than in the non-user group (5.2 ± 12.3) [p < 0.001]. In a bootstrap-type analysis of covariance adjusted for age, sex and CCI score, the use of DAPs predicted the number of days spent in hospital (p = 0.011). CONCLUSIONS: The use of DAPs in older patients with stable CVD was associated with an increased number of hospital days but not with mortality.
BACKGROUND: Many potentially inappropriate drugs prescribed to older people have anticholinergic properties as adverse effects and are therefore potentially harmful. These effects typically include constipation, dry mouth, blurred vision, dizziness and slowing of urination. It has been shown that drugs with anticholinergic properties (DAPs) are associated with cognitive decline and dementia, may contribute to events such as falls, delirium and impulsive behaviour, are associated with self-reported adverse effects and physical impairment, and may even be associated with mortality. However, studies of the prognostic implications of DAPs remain scarce. OBJECTIVE: To evaluate the impact of DAPs on hospitalization and mortality in older patients with stable cardiovascular disease (CVD). METHODS: This was a prospective study with a mean follow-up of 3.3 years involving two study groups: users (n = 295) and non-users (n = 105) of DAPs. The participants were 400 community-dwelling older people (aged 75-90 years) with stable CVD participating in a secondary prevention study of CVD (DEBATE) in Helsinki, Finland. The use of DAPs was estimated using definitions from the previous scientific literature. The Charlson Comorbidity Index (CCI) was used to estimate the burden of co-morbidity and the Mini-Mental State Examination test was used to assess cognitive function. The risks in the two study groups for hospital visits, number of days spent in hospital care and mortality were measured from 2000 to the end of 2003. RESULTS: The unadjusted follow-up mortality was 20.7% and 9.5% among the users and non-users of DAPs, respectively (p = 0.010). However, the use of DAPs was not a significant predictor of mortality in multivariate analysis after adjustment for age, sex and CCI score (hazard ratio 1.57; 95% CI 0.78, 3.15). The mean ± SD number of hospital days per person-year was higher in the DAP user group (14.9 ± 32.5) than in the non-user group (5.2 ± 12.3) [p < 0.001]. In a bootstrap-type analysis of covariance adjusted for age, sex and CCI score, the use of DAPs predicted the number of days spent in hospital (p = 0.011). CONCLUSIONS: The use of DAPs in older patients with stable CVD was associated with an increased number of hospital days but not with mortality.
Authors: Elizabeth A Chrischilles; Rachel VanGilder; Kara Wright; Michael Kelly; Robert B Wallace Journal: J Am Geriatr Soc Date: 2009-06 Impact factor: 5.562
Authors: Eija Lönnroos; Danijela Gnjidic; Sarah N Hilmer; J Simon Bell; Hannu Kautiainen; Raimo Sulkava; Sirpa Hartikainen Journal: Drugs Aging Date: 2012-05-01 Impact factor: 3.923
Authors: Arslan Shaukat; Amir Habib; Kathleen A Lane; Changyu Shen; Saba Khan; Yaron M Hellman; Malaz Boustani; Adnan S Malik Journal: Drugs Aging Date: 2014-10 Impact factor: 3.923
Authors: Satabdi Chatterjee; Vishal Bali; Ryan M Carnahan; Hua Chen; Michael L Johnson; Rajender R Aparasu Journal: Drugs Aging Date: 2017-09 Impact factor: 3.923